The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case
A hospital can meet every CMS posting rule and still face an FTC deception case over the estimate a patient receives.
A hospital can meet every CMS posting rule and still face an FTC deception case over the estimate a patient receives.
The drug file reaches manufacturers, and the schema due around May 2027 decides how much net price becomes public.
Exclusion only works as leverage when the excluded drug has no market. Mounjaro has one, and Lilly built the channel.
France has moved the reimbursement threat from price to presence: a competitor’s launch can now put an incumbent under review.
Latvia is buying access with manufacturers’ money, inside a reimbursement budget NVD already expects to overrun.
The numbers are small, but the rule is unusual: New Zealand funds by tumour type and protocol rather than product by product.
One reimbursement decision moved a second-line PD-1 into first line across three common cancers, inside biomarker limits.
The premium headline is real, but part of the cost has moved from the monthly bill to the point of care.
The injection keeps hospital claims paid for two months. It does not change the arithmetic that created the gap.
A debate about who sets the evidence bar, landing the same week Germany’s health ministry proposed lowering it.